Sfoglia per Autore

opzioni
Mostrati risultati da 1 a 20 di 89
Titolo Data di pubblicazione Autore(i) File
ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells. 2003 VALABREGA G; FAGIOLI F; CORSO S; MADON E; BRACH DEL PREVER A; BIASIN E; LINARI A; M. AGLIETTA; GIORDANO S.
Trastuzumab-based combination therapy for breast cancer 2004 MONTEMURRO F; VALABREGA G; AGLIETTA M
Controversies in breast cancer: adjuvant and neoadjuvant therapy 2005 F. MONTEMURRO; S. REDANA; G. VALABREGA; M. AGLIETTA
The 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13-17 May, 2005 2005 MONTEMURRO F; VALABREGA G; GARETTO L; ALIBERTI S; GRIGNANI G; ORTEGA C; LEONE F; PONZONE R; AGLIETTA M
TGFalpha expression impairs Trastuzumab-induced HER2 downregulation 2005 VALABREGA G; MONTEMURRO F; SAROTTO I; PETRELLI A; RUBINI P; TACCHETTI C; AGLIETTA M; COMOGLIO PM; GIORDANO S
Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy 2006 F. MONTEMURRO; M. DONADIO; M. CLAVAREZZA; S. REDANA; M.E. JACOMUZZI; G. VALABREGA; S. DANESE; G. VIETTI-RAMUS; A. DURANDO; M. VENTURINI; M. AGLIETTA
Trastuzumab treatment in breast cancer 2006 MONTEMURRO F; VALABREGA G; AGLIETTA M
Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer 2006 MONTEMURRO F; GATTI M; REDANA S; JACOMUZZI ME; NANNI D; DURANDO A; POPOLO M; PONZONE R; ROSSI A; ALBIERI V; VALABREGA G; SISMONDI P; GABRIELE P; AGLIETTA M
Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity 2007 MONTEMURRO F; VALABREGA G; AGLIETTA M
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer 2007 VALABREGA G; MONTEMURRO F; AGLIETTA M
Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference San Antonio, TX, USA, 14-17 December 2007 2007 MONTEMURRO F; REDANA S; VALABREGA G; AGLIETTA M
Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial 2008 MONTEMURRO F; REDANA S; VALABREGA G; MARTINELLO R; AGLIETTA M; PALMIERO R
Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era 2008 Montemurro F; Redana S; Viale G; Sanna G; Donadio M; Valabrega G; del Curto B; Bottini A; Botti G; Paolo dei Tos A; Jacomuzzi ME; Di Bonito M; Danese S; Clavarezza M; Kulka J; Di Palma S; Durando A; Sapino A; Aglietta M
Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study 2008 MONTEMURRO F; REDANA S; NOLE' F; DONADIO M; JACOMUZZI ME; VALABREGA G; VIALE G; SAPINO A; AGLIETTA M
Trastuzumab Beyond Disease Progression: Case Closed? 2009 Valabrega G; Aglietta M; Montemurro F
Multitarget drugs: the present and the future of cancer therapy 2009 Petrelli A; Valabrega G.
Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer. 2010 Montemurro F; Rossi V; Nolè F; Redana S; Donadio M; Martinello R; Verri E; Valabrega G; Rocca MC; Jacomuzzi ME; Viale G; Sapino A; Aglietta M.
Role of trastuzumab in the management of HER2-positive metastatic breast cancer. 2010 Milani A;Montemurro F;Gioeni L;Aglietta M;Valabrega G
Trastuzumab Beyond Progression in Retrospective Analyses: An Issue of Equal Opportunities. 2011 Montemurro F; Redana S; Geuna E; Milani A; Rossi V; Martinello R; Valabrega G; Aglietta M.
Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity? 2011 Geuna E; Milani A; Redana S; Rossi V; Valabrega G; Aglietta M; Montemurro F.
Mostrati risultati da 1 a 20 di 89
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile